News & Events
Category: COVID-19 21 April 2021
Richmond Research Institute asks the question, 'Do post-COVID-19 patients need a second dose of vaccine?'
Richmond Research Institute is actively involved in COVID-19 symptoms testing for all staff and visitors who attempt entry to Richmond Pharmacology's London bridge clinical trial unit. The data accumulated throughout this period before and after vaccination has led to the following publication: 'Do post-COVID-19 patients need a second dose of vaccine?
Category: COVID-19 19 April 2021
Do we still need challenge trials with COVID-19?
A response to a Human Challenge statement in the BMJ by Nir Eyal and colleagues.
Category: Press Releases 11 April 2021
Accelero contributes tp CombiGene AB’s Gene Therapy Program for Epilepsy
Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.
Category: Publications 6 April 2021
Novel rate-controlled fentanyl patch shows promise in phase I clinical trial
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Category: Publications 18 March 2021
A new era for UK-Japanese scientific relations
As the UK and Japan embark on a new trade deal, there are aspirations of greater collaboration and investment between the two nations. Dr Jorg Taubel shares his thoughts on the future needs of the Japanese pharmaceutical market and how UK-Japanese scientific relations can support this in his recent article in the Pharmaceutical Market Europe and PMLive.
Category: Press Releases 19 February 2021
Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy
Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.
Category: Publications 19 January 2021
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Co-authored by Christian Wolf
Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L.
Neurology. 20219; 96:e376-e386. https://doi.org/10.1212/WNL.0000000000011275.
Category: Publications 18 November 2020
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
Co-authored by Christian Wolf
Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Kappos L.
Multiple Sclerosis Journal 2020; Nov 18:1352458520971819, https://doi.org/10.1177/1352458520971819 (open access).
Category: Press Releases 10 November 2020
Marking a milestone for gene editing
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001.
Category: Events 2 September 2020